Results 151 to 160 of about 29,739 (258)
International Journal of Cancer, Volume 158, Issue 7, Page 1775-1784, 1 April 2026.Abstract The integration of modern systemic therapies with radiotherapy (RT) represents a promising strategy in breast cancer management, enhancing both locoregional control and systemic disease outcomes. This expert consensus from the Institut Curie Breast Radiotherapy Group focuses exclusively on modern systemic agents, synthesizing current evidence ...
Cezara Cheptea +5 more
wiley +1 more source
International Journal of Cancer, Volume 158, Issue 7, Page 1821-1835, 1 April 2026.What's new? Most patients with ovarian cancer (OC) relapse after first‐line chemotherapy, and prognosis with second‐line treatment depends largely on the platinum‐free interval. However, reliable biomarkers to predict response to second‐line therapy remain lacking.
Muhammad Habiburrahman +7 more
wiley +1 more source
Molecular characterisation of the Bacillus subtilis SpbK antiphage defence system
Nature CommunicationsBacteria have a variety of mechanisms for limiting predation by phages. SpbK is a Toll/interleukin-1 receptor (TIR) domain-containing antiphage defence protein from Bacillus subtilis that provides protection against the temperate phage SPβ via abortive ...
Biswa P. Mishra +15 more
doaj +1 more source
International Journal of Cancer, Volume 158, Issue 7, Page 1927-1940, 1 April 2026.What's new? Endocrine drugs repurposed from treatment protocols are the primary medications available for breast cancer (BC) prevention in at‐risk women. Adverse effects, however, significantly minimize uptake and prevention impact. Here, the authors investigated licochalcone A (LicA), a non‐endocrine anti‐inflammatory agent with reported hematologic ...
Atieh Hajirahimkhan +14 more
wiley +1 more source
Specific cyclic ADP-ribose phosphohydrolase obtained by mutagenic engineering of Mn2+-dependent ADP-ribose/CDP-alcohol diphosphatase. [PDF]
Sci Rep, 2018 Ribeiro JM +7 more
europepmc +1 more source
International Journal of Cancer, Volume 158, Issue 6, Page 1617-1627, 15 March 2026.What's new? PARP inhibitors are effective in patients with inactivating alterations in the BRCA1/2 genes across tumor types. However, the efficacy of PARP inhibitors in patients with other inactivated homologous recombination repair genes remains unclear. This knowledge gap and discrepancies in EMA/FDA approvals highlight the need for better biomarkers.
Ilse A. C. Spiekman +15 more
wiley +1 more source
Protein tyrosine phosphatase 1B is a mediator of cyclic ADP ribose-induced Ca2+ signaling in ventricular myocytes. [PDF]
Exp Mol Med, 2017 Park SA +5 more
europepmc +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 618-628, March 2026.We present model‐informed selection of the recommended dose for expansion (RDE) of investigational oral ATR inhibitor tuvusertib, by integrating clinical pharmacokinetics (PK), pharmacodynamics (PD), and safety data from DDRiver Solid Tumors 301 trial Part A1 (NCT04170153).
Jatinder Kaur Mukker +20 more
wiley +1 more source
Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels. [PDF]
Proc Natl Acad Sci U S A, 2017 Liu J +8 more
europepmc +1 more source
IJU Case Reports, Volume 9, Issue 2, March 2026.ABSTRACT Introduction BRCA2 alterations and high tumor mutational burden (TMB‐H) are responsible for prostate cancer; however, their co‐occurrence is uncommon, and evidence for PARP inhibition in the castration‐sensitive setting remains limited. We describe a case of metastatic castration‐resistant prostate cancer (CRPC) harboring both biomarkers ...
Kotaro Yokota +6 more
wiley +1 more source